These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1288 related articles for article (PubMed ID: 30198439)

  • 21. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
    Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
    Guidi A; Codecà C; Ferrari D
    Med Oncol; 2018 Feb; 35(3):37. PubMed ID: 29441454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
    Bhatia A; Burtness B
    Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Moskovitz J; Moy J; Ferris RL
    Curr Oncol Rep; 2018 Mar; 20(2):22. PubMed ID: 29502288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
    Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
    Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ["Immunotherapy in head and neck squamous cell carcinoma"].
    Marret G; Borcoman É; Le Tourneau C
    Rev Prat; 2021 Apr; 71(4):396-399. PubMed ID: 34161005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer.
    Le X; Ferrarotto R; Wise-Draper T; Gillison M
    J Natl Compr Canc Netw; 2020 Jul; 18(7):899-906. PubMed ID: 32634775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Role of Dacomitinib in Head and Neck Cancer.
    Elicin O; Ozsahin M
    Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
    Przybylski K; Majchrzak E; Weselik L; Golusiński W
    Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
    Hughes RT; Gebeyehu RR; Kalada JM; Lycan TW; Frizzell BA; Kinney RD; D'Agostino RB; Bunch PM; Triozzi P; Zhang W; Furdui CM; Porosnicu M
    Future Oncol; 2023 Jul; 19(22):1523-1534. PubMed ID: 37199326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
    Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
    Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
    Mody MD; Gill HS; Saba NF
    JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy of head and neck cancer : Highlights of the ASCO and ESMO annual meetings 2021].
    Theodoraki MN; Laban S; Hoffmann TK
    HNO; 2022 Apr; 70(4):271-277. PubMed ID: 35037989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
    Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
    Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing Recurrent Metastatic Head and Neck Cancer.
    Shaikh H; Karivedu V; Wise-Draper TM
    Hematol Oncol Clin North Am; 2021 Oct; 35(5):1009-1020. PubMed ID: 34226077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
    Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
    Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
    Sheth S; Weiss J
    Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.